Albania vs Bhutan: HIV/AIDS deaths averted by antiretroviral therapy
Albania
51.15 deaths
in 2024
Bhutan
39.56 deaths
in 2024
Albania rank
135th
Bhutan rank
138th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Albania
- Bhutan
How they compare
Albania currently reports 51.15 deaths against 39.56 deaths in Bhutan, a difference of 11.59 deaths.
That makes Albania's figure about 1.3 times Bhutan's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Bhutan ahead.
Albania ranks 135th and Bhutan ranks 138th of 157 countries.
Albania has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Albania | Bhutan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 4.99 deaths | 2.06 deaths | 2.93 deaths | Albania |
| 2010s | 35.4 deaths | 18.6 deaths | 16.8 deaths | Albania |
| 2020s | 48.41 deaths | 35.68 deaths | 12.73 deaths | Albania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Albania or Bhutan?
- Albania, at 51.15 deaths against 39.56 deaths in Bhutan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Albania and Bhutan?
- 11.59 deaths, with Albania ahead.
- How many years of comparable data are there for Albania and Bhutan?
- 35 years are reported by both, from 1990 to 2024.
- How do Albania and Bhutan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Albania ranks 135th and Bhutan ranks 138th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.